196 related articles for article (PubMed ID: 21255957)
1. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ; Gordon A; Johansson J; Wolski K; Ballantyne CM; Kastelein JJ; Taylor A; Borgman M; Nissen SE
J Am Coll Cardiol; 2011 Mar; 57(9):1111-9. PubMed ID: 21255957
[TBL] [Abstract][Full Text] [Related]
2. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Bailey D; Jahagirdar R; Gordon A; Hafiane A; Campbell S; Chatur S; Wagner GS; Hansen HC; Chiacchia FS; Johansson J; Krimbou L; Wong NC; Genest J
J Am Coll Cardiol; 2010 Jun; 55(23):2580-9. PubMed ID: 20513599
[TBL] [Abstract][Full Text] [Related]
3. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
[TBL] [Abstract][Full Text] [Related]
4. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Wong NC; Borgman MR; Nissen SE
Cardiovasc Drugs Ther; 2012 Apr; 26(2):181-7. PubMed ID: 22349989
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein A-I therapy promise, challenges, and disappointment.
Davidson MH
J Am Coll Cardiol; 2011 Mar; 57(9):1120-1. PubMed ID: 21255956
[No Abstract] [Full Text] [Related]
6. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.
Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; van Hall G; Cobelli C; Dalla-Man C; Otvos JD; Rye KA; Johansson J; Gordon A; Wong NC; Sviridov D; Barter P; Duffy SJ; Meikle PJ; Kingwell BA
Metabolism; 2016 Jun; 65(6):904-14. PubMed ID: 27173469
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg WA; Holme I; Boekholdt SM; Larsen ML; Lindahl C; Stroes ES; Tikkanen MJ; Wareham NJ; Faergeman O; Olsson AG; Pedersen TR; Khaw KT; Kastelein JJ
J Am Coll Cardiol; 2008 Feb; 51(6):634-42. PubMed ID: 18261682
[TBL] [Abstract][Full Text] [Related]
8. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.
Mani P; Uno K; St John J; Tuzcu EM; Nissen SE; Nicholls SJ
Am J Cardiol; 2014 Sep; 114(5):681-5. PubMed ID: 25030535
[TBL] [Abstract][Full Text] [Related]
9. LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Ruff CT; Koren MJ; Grimsby J; Rosenbaum AI; Tu X; Karathanasis SK; Falloon J; Hsia J; Guan Y; Conway J; Tsai LF; Hummer BT; Hirshberg B; Kuder JF; Murphy SA; George RT; Sabatine MS
Arterioscler Thromb Vasc Biol; 2021 Dec; 41(12):3005-3014. PubMed ID: 34706556
[TBL] [Abstract][Full Text] [Related]
10. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Jahagirdar R; Zhang H; Azhar S; Tobin J; Attwell S; Yu R; Wu J; McLure KG; Hansen HC; Wagner GS; Young PR; Srivastava RA; Wong NC; Johansson J
Atherosclerosis; 2014 Sep; 236(1):91-100. PubMed ID: 25016363
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Michael Gibson C; Korjian S; Tricoci P; Daaboul Y; Yee M; Jain P; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea DM; Deckelbaum LI; Merkely B; Zarebinski M; Ophuis TO; Harrington RA
Circulation; 2016 Dec; 134(24):1918-1930. PubMed ID: 27881559
[TBL] [Abstract][Full Text] [Related]
13. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Ballantyne CM; Shah S; Sapre A; Ashraf TB; Tobias SC; Sahin T; Ye P; Dong Y; Sheu WH; Kang DH; Ferreira Rossi PR; Moiseeva Y; Briones IR; Johnson-Levonas AO; Mitchel YB
Am J Cardiol; 2017 Aug; 120(4):569-576. PubMed ID: 28624096
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
16. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
17. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
[TBL] [Abstract][Full Text] [Related]
18. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC; Gordon A; McLure K; Young P
Atherosclerosis; 2016 Apr; 247():48-57. PubMed ID: 26868508
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
20. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Schaefer JR; Schweer H; Ikewaki K; Stracke H; Seyberth HJ; Kaffarnik H; Maisch B; Steinmetz A
Atherosclerosis; 1999 May; 144(1):177-84. PubMed ID: 10381291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
